These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 34094628)

  • 1. Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020.
    Morikane K; Satoh N; Hatano K; Kanouchi K; Kakehata S; Satoh S; Uyeki TM; Ueno Y
    Western Pac Surveill Response J; 2021; 12(1):69-71. PubMed ID: 34094628
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study.
    Schaffner A; Risch L; Weber M; Thiel S; Jüngert K; Pichler M; Wohlwend N; Lung T; Ritzler M; Hillmann D; Copeland S; Renz H; Paprotny M; Risch M
    Clin Chem Lab Med; 2020 Nov; 59(2):e49-e51. PubMed ID: 33554502
    [No Abstract]   [Full Text] [Related]  

  • 4. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital.
    Madhusudan M; Sankar J; Dhanalakshmi K; Putlibai S; Balasubramanian S
    Indian Pediatr; 2021 Mar; 58(3):279-280. PubMed ID: 33713065
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults.
    Rytter MJH; Nygaard U; Mandic IN; Glenthøj JP; Schmidt LS; Cortes D; Smith B; Zaharov T; Søndergaard MJ; Lawaetz MC; Saekmose S; Jensen LH; Schmiegelow K; Kristensen K
    Pediatr Infect Dis J; 2021 Apr; 40(4):e157-e159. PubMed ID: 33427800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study.
    Brehm TT; Schwinge D; Lampalzer S; Schlicker V; Küchen J; Thompson M; Ullrich F; Huber S; Schmiedel S; Addo MM; Lütgehetmann M; Knobloch JK; Schulze Zur Wiesch J; Lohse AW
    Int J Hyg Environ Health; 2021 Mar; 232():113671. PubMed ID: 33338782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 IgG seroprevalence among medical staff in a general hospital that treated patients with COVID-19 in Japan: retrospective evaluation of nosocomial infection control.
    Hibino M; Iwabuchi S; Munakata H
    J Hosp Infect; 2021 Jan; 107():103-104. PubMed ID: 33039454
    [No Abstract]   [Full Text] [Related]  

  • 9. Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam.
    Chau NVV; Toan LM; Man DNH; Thao HP; Lan NPH; Ty DTB; Hieu DK; Tien NTM; Ngoc NM; Hung LM; Dung NT; Thanh TT; Truong NT; Thwaites G; Tan LV
    J Infect; 2021 Jan; 82(1):e36-e37. PubMed ID: 33221367
    [No Abstract]   [Full Text] [Related]  

  • 10. Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors.
    Razafimahatratra SL; Ndiaye MDB; Rasoloharimanana LT; Dussart P; Sahondranirina PH; Randriamanantany ZA; Schoenhals M
    Lancet Glob Health; 2021 Oct; 9(10):e1363-e1364. PubMed ID: 34534478
    [No Abstract]   [Full Text] [Related]  

  • 11. Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022.
    Kinoshita R; Arashiro T; Kitamura N; Arai S; Takahashi K; Suzuki T; Suzuki M; Yoneoka D
    Emerg Infect Dis; 2023 Sep; 29(9):1868-1871. PubMed ID: 37506681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?
    Takahashi S; Greenhouse B; Rodríguez-Barraquer I
    J Infect Dis; 2020 Nov; 222(11):1772-1775. PubMed ID: 32856712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
    Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
    Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.
    Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M
    Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can we interpret SARS-CoV-2 antibody test results?
    Føns S; Krogfelt KA
    Pathog Dis; 2021 Feb; 79(1):. PubMed ID: 33512464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria.
    Egger M; Bundschuh C; Wiesinger K; Bräutigam E; Berger T; Clodi M; Dieplinger B
    Clin Chem Lab Med; 2021 May; 59(6):e231-e234. PubMed ID: 33554543
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
    Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
    Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV).
    Kindgen-Milles D; Brandenburger T; Braun JFW; Cleff C; Moussazadeh K; Mrosewski I; Timm J; Wetzchewald D
    PLoS One; 2021; 16(4):e0248813. PubMed ID: 33831032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.